Scientific Publications

The following list of key scientific articles have been authored by the founding research team of ActoGeniX and their collaborators and published in renowned, peer-reviewed journals.

  1. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Reviews Microbiology 2008; published online March 17th
  2. Waeytens A, Ferdinande L, Neirynck S, Rottiers P, De Vos M, Steidler L, Cuvelier C. Paracellular entry of Interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflammatory Bowel Disease 2008; 14(4):471-9.
  3. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. Journal of Allergy and Clinical Immunology 2007; 119, 952-959.
  4. Huibregtse IL, Snoeck V, De Creus A, Braat H, De Jong EC, Van Deventer SJH, Rottiers P. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007; 133(2), 517-528.
  5. Steidler L & Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. In: Inflammatory Bowel Disease: Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways, Annals of the New York Academy of Sciences 2006; Vol. 1072, 176-186.
  6. Steidler L & Vandenbroucke K. Genetically modified Lactococcus lactis: novel tools for drug delivery. International Journal of Dairy Technology 2006; 59, 140-146.
  7. Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, Remaut E, Rottiers P. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Applied and Environmental Microbiology 2006; 72(12), 7694-7700.
  8. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L. A Phase I trial with transgenic bacteria expressing Interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology 2006; 4(6), 754-759.
  9. Remaut E, Braat H, Vandenbroucke K, Rottiers P, Steidler L. Clinical potential of Lactococcus lactis mediated delivery of human Interleukin-10 and Trefoil Factors. Bioscience Microflora 2006; 25, 81-97.
  10. Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann N Y Acad Sci 2006; 1072, 176-186.
  11. Huyghebaert N, Vermeire A, Rottiers P, Remaut E, Remon JP. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. European Journal of Pharmaceutics and Biopharmaceutics 2005; 61(3), 134-141.
  12. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. European Journal of Pharmaceutics and Biopharmaceutics 2005; 59, 9-15.
  13. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127(2), 502-513.
  14. Steidler L. Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology? Expert Opinion on Biological Therapy 2004; 4, 439-441.
  15. Steidler L. Genetically engineered probiotics. Best Practice & Research in Clinical Gastroenterology 2003; 17, 861-876.
  16. Steidler L & Neirynck S. In situ delivery of therapeutic proteins by recombinant Lactococcus lactis. Journal of Microbiology 2003; 41, 63-72.
  17. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human Interleukin-10. Nature Biotechnology 2003; 21(7), 785-789.
  18. Steidler L. Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes and Infection 2001; 3, 1157-1166.
  19. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting Interleukin-10. Science 2000; 289(5483), 1352-1355.
  20. Steidler L, Robinson K, Chamberlain L, Schofield KM, Remaut E, Le Page RWF, Wells JM. Mucosal delivery of murine Interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis co-expressing antigen and cytokine. Infection and Immunity 1998; 66, 3183-3189.